Market capitalization | $2.89b |
Enterprise Value | $2.33b |
P/E (TTM) P/E ratio | 61.27 |
EV/FCF (TTM) EV/FCF | 6.94 |
EV/Sales (TTM) EV/Sales | 11.19 |
P/S ratio (TTM) P/S ratio | 13.90 |
P/B ratio (TTM) P/B ratio | 4.19 |
Revenue growth (TTM) Revenue growth | -34.02% |
Revenue (TTM) Revenue | $207.80m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
11 Analysts have issued a Protagonist Therapeutics, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 208 208 |
34%
34%
|
|
Gross Profit | 205 205 |
34%
34%
|
|
EBITDA | 30 30 |
81%
81%
|
EBIT (Operating Income) EBIT | 27 27 |
82%
82%
|
Net Profit | 56 56 |
65%
65%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
Head office | United States |
CEO | Dinesh Patel |
Employees | 126 |
Founded | 2006 |
Website | www.protagonist-inc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.